CDK6


Also found in: Acronyms.

CDK6

A gene on chromosome 7q21-q22 that encodes a cyclin-dependent kinase, which is a catalytic subunit of the protein kinase complex important in cell cycle G1-phase progression and G1/S transition. CDK6, with CDK4, phosphorylates and regulates the activity of tumour suppressor protein Rb.

Molecular pathology
CDK6 expression is upregulated in some cancers.
References in periodicals archive ?
Consistent with the results of the FACS assay, the expression of cyclin D1, CDK4 and CDK6 was down-regulated after 24 h-AB23 treatment (Fig.
The two cell-cycle kinases CDK4 and CDK6 normally facilitate cell-cycle progression but are abnormally activated in certain cancers.
As to the mechanisms, levels of inactive or phosphorylated (p) p53, p21, CDK6, CDK4, cyclin Dl, and E2F1 were immunodetected.
2] Human genes: EGFR, epidermal growth factor receptor; KRAS, kirsten rat sarcoma viral oncogene homolog; ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; EML4, echinoderm microtubule-associated protein like 4; ALK, anaplastic lymphoma receptor tyrosine kinase; SEPT9, septin 9; CDKN2A, cyclin-dependent kinase inhibitor 2A; MET, MET proto-oncogene, receptor tyrosine kinase; CDK6, cyclin-dependent kinase 6; BRAF, B-Raf proto-oncogene, serine/threonine kinase.
Kip1) cell cycle 2006 progression 8 CDK6 Probably involved in Chilosi et al.
Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation.
PQ relies on the use of potent and selective inhibitors of cellular enzymes called CDK4 and CDK6.
La ciclina CD1 se une y activa a CDK4 y CDK6, promoviendo el paso de G1/S.
Antibodies against cyclin D1, phospho-cyclin D1 (Thr286), HA-tag, CDK4, CDK6 and /S-actin were purchased from Cell Signaling (Bervely, MA, USA).
The germline mutation on VHL is a cause of von Hippel-Lindau syndrome); CCND1, cyclin D1 (cyclin D1 controls cell cycle by regulating CDK4 and CDK6 activity which is required for G1/S transition); CDKN2A, cyclin dependent kinase inhibitor 2A (cyclin dependent kinase inhibitor 2A regulates cell cycle G1 progression by inhibiting CDK4 kinase.
The technology has already been successfully utilised to find key cancer mutations, including amplifications in ERBB2 (HER2/neu), MET and CDK6, in cancer patients' blood.
Antibodies against Bach1 (sc-14700), Bcl2 (sc-7382), Bcl-xL (sc-8392), HO-1 (sc-1796), cyclin D1 (sc-20044), cyclin E2 (sc-28351), cyclin B1 (sc-595), CDK2 (sc-163), CDK4 (sc-601), CDK6 (sc-177), p21 (sc-397), p53 (sc-126), the human Bach1 siRNA (sc-37064), and the control siRNA were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).